Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Durvalumab

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Durvalumab is a selective, high-affinity, human IgG1 monoclonal antibody that blocks PD-L1, which binds to PD-1 and CD80, but not to PD-L2.
Mezquita & Planchard 2018 Future Oncology 14: 205-222…

References (Sources)

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
Ning et al. 2018
Durvalumab in non-small-cell lung cancer patients: current developments
Mezquita & Planchard 2018 Future Oncology 14: 205-222
Durvalumab: First Global Approval
Syed 2017
Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Huang & Zhang, 2017 Current Cancer Therapy Reviews 13: 120-128
Second- and third-generation drugs for immuno-oncology Treatment - The more the better?
Dempke et al. 2017 European Journal of Cancer 74: 55e72
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Durvalumab

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat

Links